GlassScriptPhysician profile
Kenneth I Fishberger
NPI 1649291451
$5,285.61
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $898 · 2021: $688 · 2022: $668 · 2023: $830 · 2024: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $679.71 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $590.80 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.26 | 2019-2024 | Tradjenta, Ofev, Synjardy |
| Novo Nordisk INC | $505.05 | 2019-2024 | |
| Pfizer INC. | $415.34 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $306.65 | 2019-2024 | Xarelto |
| Allergan, INC. | $284.37 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $256.23 | 2019-2023 | |
| Lilly USA, LLC | $242.05 | 2019-2022 | |
| Amarin Pharma, INC. | $215.36 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $212.43 | 2019-2024 | Livalo |
| Astrazeneca Pharmaceuticals LP | $196.46 | 2019-2024 | Farxiga |
| Abbott Laboratories | $152.71 | 2019-2024 | Freestyle Libre 3 |
| Astellas Pharma US INC | $108.38 | 2019-2024 | Veozah, Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $83.12 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $81.95 | 2019-2021 | |
| Daiichi Sankyo INC. | $67.39 | 2019-2023 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $64.13 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $60.35 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $41.85 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $32.43 | 2019 | |
| Mylan Specialty L.P. | $24.72 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.59 | 2024 | Trulance, Xifaxan |
| Horizon Therapeutics Plc | $17.36 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.94 | 2019 | |
| Scilex Pharmaceuticals INC. | $15.53 | 2019 | |
| Sanofi Pasteur INC. | $12.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Fishberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.